Fundz

Pfizer Ventures Co-Leads £40M Funding In Grey Wolf Therapeutics

PRIVATEJan 27, 2023

Amount Raised

£40 Million

Round Type

Funding Round

MiltonBiotechnologyHealth CareMedicalTherapeutics

Description

The corporate venture capital arm of Covid-19 vaccine maker Pfizer has co-led a $49m (£39.6m) investment into Oxford-based biotech startup Grey Wolf, which develops immuno-oncology therapeutic technology.

Who to call at Grey Wolf Therapeutics, and when

A new round usually means Grey Wolf Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Grey Wolf Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Grey Wolf Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Grey Wolf Therapeutics

Location

Milton, Oxfordshire, United Kingdom

About

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery. For more information, visit the website or email enquiries@gwt.bio.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Grey Wolf Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsLisa S., Co-Founder & CSO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Grey Wolf Therapeutics's next move

See what Strategic adds

Grey Wolf Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.